The biotech industry raised $2.3 billion via 31 follow-on deals in 1Q13. This compares to $2.1 billion via 35 deals in 1Q12. In the after-market, the range of gains and losses was -23% to +55%, but only seven companies are now trading below their post-money valuations. The 1Q13 follow-on class is up a median of 7%.

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) and Celldex Therapeutics Inc. (NASDAQ:CLDX) were both up more than 50% since their follow-ons. In March, Aegerion said it expects global net revenues of $15-$25 million for FY13 with 250-300 patients on Juxtapid lomitapide globally by year end. FDA approved Juxtapid in December